Insulet Corp. (NSDQ:PODD) is hoping to win 510(k) clearance* for a new Omnipod officials said will help the company reduce its production costs by more than a third.
Diabetes: Insulet seeks FDA nod for next-generation OmniPod insulin pump
Insulet
Insulet looks north of the border with GlaxoSmithKline deal
UPDATED 3/3/2011 10:20 a.m.
Insulet Corp. (NSDQ:PODD) inked a Canadian distribution deal with GlaxoSmithKline plc (NYSE:GSK) for its OmniPod insulin management system.
The deal gives the British pharma giant — stung by recent problems with its Avandia diabetes drug — exclusive rights to market and sell Bedford, Mass.-based Insulet’s OmniPod system north of the border.
Insulet inks Canadian deal with GlaxoSmithKline | Distribution roundup
Insulet Corp. (NSDQ:PODD) inked a Canadian distribution deal with GlaxoSmithKline plc (NYSE:GSK) for its OmniPod insulin management system.
The deal gives the British pharma giant — stung by recent problems with its Avandia diabetes drug — exclusive rights to market and sell Bedford, Mass.-based Insulet’s OmniPod system north of the border.
Insulet’s Q4 losses widen but 2010 losses fall 16 percent | Earnings roundup
MassDevice keeps a close eye on public medical device companies, tracking their quarterly sales and earnings reports. For the most recent filings, check out our Earnings Roundup, where we collect each quarter’s reports.
Here’s a quick rundown of a few releases over the past couple days:
Insulet pays off Deerfield loan
Insulet Corp. (NSDQ:PODD) paid off a $60 million credit facility with Deerfield Partners more than nine months ahead of schedule, with a $33.3 million payment it says will save $5 million.
The Bedford, Mass.-based insulin management company took out the credit line in March 2009, drawing $27.5 million almost immediately and keeping another $32.5 million available.
Earnings roundup: Insulet revenue jumps 36 percent as losses narrow
Insulet revenue jumps 36 percent as losses narrow
Insulet Corp. (NSDQ:PODD) reported a loss of $12.1 million, or 30 cents per diluted share, on revenue of $25.5 million during the three months ended Sept. 30. That compares with a loss of $16.9 million, or 60 cents per diluted share, on revenue of $18.7 million during the same period last year.
Insulet COO Malave jumps ship to helm Palyon Medical
Luis Malave, COO for Insulet Corp. (NSDQ:PODD), is jumping ship effective August 31 to man the helm of Palyon Medical Corp.
Malave’s eight-year tenure at the Bedford, Mass.-based insulin management system maker saw the company ramp up its capabilities to produce 1 million of Insulet’s flagship OmniPods per quarter.
Insulet Corp. records 57% jump in 2Q revenues
Insulet Corp. (Nasdaq:PODD) is moving into its second decade as a business looking at new markets for its OmniPod insulin infusion device, improving sales, better terms on its long-term debt and a little extra cash.
But it’s still fighting a problem that’s as old as the company: Net losses typically running out to eight digits.
Insulet’s Q1 earnings beat Wall Street’s forecast by a penny
Riding a 67 percent jump in first quarter revenues, insulin pump-maker Insulet Corp. (NSDQ:PODD) significantly narrowed its net loss compared to year-ago levels and beat Wall Street estimates by 1 cent per share during the three months ended March 31.
Insulet beats Q4, full-year expectations
Insulet Corp. (NSDQ:PODD) continued down the road to profitability, increasing its fourth-quarter and full-year revenues and narrowing its net losses by 48.9 percent and 16.1 percent, respectively.
The Bedford, Mass.-based insulin management system maker posted a net loss of $14.9 million, or 42 cents per share, on sales of $20.2 million during the three months ended Dec. 31, 2009, compared with net losses of $29.2 million, or $1.05 per share, on sales of $11.9 million during the fourth quarter of 2008.
UPDATE: Insulet inks 5-year, $100 million, 11-nation OmniPod distribution deal
The OmniPod is going global.
Bedford, Mass.-based Insulet Corp. (NSDQ:PODD) signed a five-year, $100 million international distribution deal with Ypsomed AG (SIX:YPSN) to exclusively distribute the insulin management system in 11 countries, including China.
